12:00 AM
May 27, 2013
 |  BC Week In Review  |  Company News  |  Deals

Aradigm, Grifols deal

Aradigm granted Grifols exclusive, worldwide rights to develop and commercialize Aradigm's formulations of inhaled ciprofloxacin - Pulmaquin liposomal ciprofloxacin and Lipoquin liposomal ciprofloxacin - to treat severe respiratory diseases, including non-cystic fibrosis bronchiectasis. Aradigm will conduct Phase III testing of Pulmaquin in non-CF bronchiectasis and will be responsible for obtaining regulatory approval for the product in the first indication in the U.S. and EU. Grifols will bear additional regulatory expenses. Grifols will...

Read the full 357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >